• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.62% Nasdaq Up0.35%

    More On TTH.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Transition Therapeutics Inc. (TTH.TO)

    1.30 0.00(0.00%) Feb 9
    ProfileGet Profile for:
    Transition Therapeutics Inc.
    101 College Street
    Suite 220
    Toronto, ON M5G 1L7
    Canada - Map
    Phone: 416-260-7770
    Website: http://www.transitiontherapeutics.com

    Index Membership:N/A
    Full Time Employees:18

    Business Summary 

    Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications primarily in Canada. The company's lead central nervous system drug candidate is ELND005, which has completed a Phase II/III clinical trial for the treatment of agitation/aggression associated with Alzheimer's disease; and has completed Phase IIa clinical trial for the treatment of Down syndrome. Its lead metabolic drug candidate is TT401, which is in Phase II clinical study for the treatment of type 2 diabetes and accompanying obesity. The company is also developing TT701, a selective androgen receptor modulator for the treatment of androgen deficiencies. Transition Therapeutics Inc. has a licensing and collaboration agreement with Eli Lilly to develop and commercialize TT401; and to develop compounds in preclinical models to provide glycemic control and other beneficial effects, including weight loss. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Transition Therapeutics Inc.

    Key Executives 
    Dr. Tony F. Cruz Ph.D., 63
    Chairman and Chief Exec. Officer
    Ms. Nicole Rusaw-George C.A, 43
    Chief Financial Officer
    Dr. Aleksandra Pastrak , 50
    VP of Clinical Devel. and Medical Officer
    Mr. Carl Damiani , 44
    Pres and Chief Operating Officer
    Mr. Louis Alexopoulos ,
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.